U.S. markets closed

Chimerix, Inc. (CMRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.81-0.86 (-8.06%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close10.67
Open10.36
Bid9.10 x 800
Ask9.95 x 2900
Day's Range9.54 - 10.78
52 Week Range1.19 - 11.57
Volume1,084,130
Avg. Volume1,171,575
Market Cap700.019M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.57
Earnings DateMay 05, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial
    PR Newswire

    Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial

    Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung diseases and cancer, today announced that Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of Cantex's DSTAT investigational product, yesterday reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI), suggesting that dociparstat sodium (DSTAT) may accelerate recovery from ALI, as well as mitigate thrombotic events in such patients. A copy of Chimerix' press release and detailed information can be found at https://ir.chimerix.com/news-releases/news-release-details/chimerix-reports-promising-topline-results-first-cohort

  • Chimerix (CMRX) Q4 2020 Earnings Call Transcript
    Motley Fool

    Chimerix (CMRX) Q4 2020 Earnings Call Transcript

    With me on today's call are President and Chief Executive Officer Mike Sherman, Chief Medical Officer Allen Melemed, Chief Financial and Business Officer Mike Andriole, Chief Science Officer Randall Lanier, and our newest member of the team, too, Chief Interim Technology Officer Josh Allen. Before we begin, I would like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors.

  • Benzinga

    Chimerix's DSTAT Shows Promising Results In First Cohort Of COVID-19 Study

    Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection. The primary endpoint of the study is survival without the need for mechanical ventilation through day 28. One patient on DSTAT was ventilated and recovered, and two patients on placebo progressed to ventilation and died. No deaths were reported in patients on the DSTAT arm. All six DSTAT patients met the clinical status assessment's improvement criteria, compared to two of the six placebo patients. No patients on DSTAT had elevated values for biomarkers related to lung inflammation and thrombotic complications. DSTAT was observed to be generally safe and well-tolerated. No patients on the DSTAT arm discontinued study treatment for adverse events compared to two patients on the placebo arm. The second cohort of 12 patients is fully enrolled, with topline data expected in the second quarter. Price Action: CMRX shares are down 1.77% at $10 in the premarket session on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaCompugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor StudiesSpringWorks Therapeutics Shows Early Action In Peripheral Nerves Tumor Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.